ロード中...
Cannabinoid CB(1) receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats
Cannabinoid CB(1) receptors (CB(1)Rs) have been shown to be a promising target in medication development for the treatment of addiction. However, clinical trials with SR141716A (rimonabant, a selective CB(1)R antagonist/inverse agonist) for the treatment of obesity and smoking cessation failed due t...
保存先:
| 出版年: | Acta Pharmacol Sin |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6460369/ https://ncbi.nlm.nih.gov/pubmed/29967454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-018-0059-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|